

ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency

NCT07473973

Status	RECRUITING
Phase	Phase 3
Sponsor	Inozyme Pharma
Enrollment	12 participants

Key Eligibility Criteria

Inclusion (6)

- Participants must meet all of the following:
- Infant aged d 1 year at the time of enrollment.
- Confirmed diagnosis of ENPP1 deficiency, based on genetic testing.
- Clinical features consistent with generalized arterial calcification of infancy (GACI) (e.g., vascular calcification or cardiac involvement).
- Medically stable to participate in a 52-week treatment study.
- ... and 1 more (see full listing online)

Exclusion (5)

- Participants will not be eligible if any of the following apply:
- Receiving end-of-life or hospice care.
- Prior treatment with INZ-701, unless received through an approved expanded access program.
- Concurrent participation in another interventional clinical trial.
- Planned major surgery during the study period that would interfere with study participation.

Locations (8 total)

Hospital Universitario Pedro Ernesto/Rio de Janeiro, Rio de Janeiro, Brazil
Hopital Necker - Enfants Malades, Paris, France
Gyermekgyogyaszat, DE, Debrecen, Hungary
... and 5 more locations